ORCID Profile
0000-0003-4445-1201
Current Organisations
Utrecht University
,
Amsterdam UMC, Univ of Amsterdam
,
Cochrane Netherlands
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Related Links
Publications
Pharmacokinetics of Oral Tenofovir Disoproxil Fumarate in Pregnancy and Lactation: A Systematic Review
Publisher: SAGE Publications
Date: 10-2018
DOI: 10.3851/IMP3341
Abstract: Tenofovir disoproxil fumarate (TDF), the oral prodrug of tenofovir (TFV), is advocated in pregnancy for prevention of mother-to-child transmission (PMCT) with failure of hepatitis B immunoglobulin and vaccination. The pharmacokinetics of TDF monotherapy for PMCT-HBV is important if deployment is to emulate the success of multiple antiretrovirals (ARVs) for PMCT-HIV in resource-constrained settings. This systematic review followed a protocol and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) guidelines. We included studies that enrolled pregnant women who received oral TDF therapy as mono-therapy or in combination with other ARVs: irrespective of the reason for receiving the drug (for ex le, HIV, HBV or pre-exposure prophylaxis) and reported pharmacokinetics. The area under the concentration–time curve (AUC), maximum plasma concentrations (C max ) and last measurable plasma concentration (C last ) of TFV were decreased in the second and third trimester compared with first trimester or post-partum. In none of the manuscripts was the non-pregnant HBV threshold of C max of 300 ng/ml reached, but the 50% effective concentration (EC 50 ) of TFV is lower for treatment of HBV compared with HIV. The TFV concentration in breastfed infants was 0.03% of the recommended infant dose. Most knowledge of pharmacokinetics of TFV in pregnancy results from studies on HIV involving multiple ARVs. Increased TFV clearance occurred in the second and third trimester when optimal TFV concentrations are required to maximize suppression of HBV in the window before birth. Dose or duration adjustments will be better conceptualized with concurrent analysis of the pharmacokinetics of TFV monotherapy and hepatitis B pharmacodynamics in pregnancy.
CLEF 2017 eHealth Evaluation Lab Overview
Publisher: Springer International Publishing
Date: 2017
A focus on cross-purpose tools, automated recognition of study design in multiple disciplines, and evaluation of automation tools: a summary of significant discussions at the fourth meeting of the Int
Publisher: Springer Science and Business Media LLC
Date: 04-05-2020
DOI: 10.1186/S13643-020-01351-4
Abstract: The fourth meeting of the International Collaboration for Automation of Systematic Reviews (ICASR) was held 5–6 November 2019 in The Hague, the Netherlands. ICASR is an interdisciplinary group whose goal is to maximize the use of technology for conducting rapid, accurate, and efficient systematic reviews of scientific evidence. The group seeks to facilitate the development and acceptance of automated techniques for systematic reviews. In 2018, the major themes discussed were the transferability of automation tools (i.e., tools developed for other purposes that might be used by systematic reviewers), the automated recognition of study design in multiple disciplines and applications, and approaches for the evaluation of automation tools.
Overview of the CLEF eHealth Evaluation Lab 2018
Publisher: Springer International Publishing
Date: 2018
Electronic and animal noses for detecting SARS-CoV-2 infection
Publisher: Wiley
Date: 28-06-2021
CLEF eHealth 2019 Evaluation Lab
Publisher: Springer International Publishing
Date: 2019
Related Organisations
Related Funding Activities
No related grants have been discovered for Rene Spijker.